Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 29
Filter
Add more filters











Publication year range
1.
Front Immunol ; 11: 539086, 2020.
Article in English | MEDLINE | ID: mdl-33574810

ABSTRACT

The neglected tropical infirmity Chagas disease (CD) presents high mortality. Its etiological agent T. cruzi is transmitted by infected hematophagous insects. Symptoms of the acute phase of the infection include fever, fatigue, body aches, and headache, making diagnosis difficult as they are present in other illnesses as well. Thus, in endemic areas, individuals with undetermined pain may be considered for CD. Although pain is a characteristic symptom of CD, its cellular and molecular mechanisms are unknown except for demonstration of a role for peripheral TNF-α in CD pain. In this study, we evaluate the role of spinal cord glial cells in experimental T. cruzi infection in the context of pain using C57BL/6 mice. Pain, parasitemia, survival, and glial and neuronal function as well as NFκB activation and cytokine/chemokine production were assessed. T. cruzi infection induced chronic mechanical and thermal hyperalgesia. Systemic TNF-α and IL-1ß peaked 14 days postinfection (p.i.). Infected mice presented increased spinal gliosis and NFκB activation compared to uninfected mice at 7 days p.i. Glial and NFκB inhibitors limited T. cruzi-induced pain. Nuclear phosphorylated NFκB was detected surrounded by glia markers, and glial inhibitors reduced its detection. T. cruzi-induced spinal cord production of cytokines/chemokines was also diminished by glial inhibitors. Dorsal root ganglia (DRG) neurons presented increased activity in infected mice, and the production of inflammatory mediators was counteracted by glial/NFκB inhibitors. The present study unveils the contribution of DRG and spinal cord cellular and molecular events leading to pain in T. cruzi infection, contributing to a better understanding of CD pathology.


Subject(s)
Chagas Disease/immunology , Cytokines/immunology , NF-kappa B/immunology , Neuroglia/immunology , Pain/immunology , Spinal Cord/immunology , Trypanosoma cruzi/immunology , Animals , Chagas Disease/pathology , Ganglia, Spinal/immunology , Ganglia, Spinal/parasitology , Ganglia, Spinal/pathology , Male , Mice , Neuroglia/parasitology , Neuroglia/pathology , Pain/parasitology , Pain/pathology , Spinal Cord/parasitology , Spinal Cord/pathology
2.
Mediators Inflamm ; 2018: 1094352, 2018.
Article in English | MEDLINE | ID: mdl-29805310

ABSTRACT

The mechanism of pain reduction involves bidirectional processes of pain blocking (nociception) and reductions in the levels of proinflammatory cytokines in the blood. Does transcutaneous electrical nerve stimulation (TENS) reduce blood levels of proinflammatory cytokines? For this systematic review, we searched in six databases to identify randomized controlled trials with the criteria: humans older than 18 years (adults), use of TENS in the experimental group, and having at least one pre- and postintervention blood level of at least one proinflammatory cytokine. The risk of bias and the level of evidence were assessed. Five studies were included involving 240 participants. The heterogeneity of the studies was high (I2: 85%); therefore, we used a random-effects meta-analysis. It was observed through the meta-analysis synthesis measures that there were statistically significant differences following the use of TENS to reduce the general group of cytokines. When grouped by chronic disease, by postoperative settings, or by individual studies in the case of IL-6, it was observed that the significant reduction of cytokines related to the use of TENS was maintained. The use of TENS reduced the blood levels of proinflammatory cytokines (we observed a protective factor of TENS in relation to inflammation). The protocol of the systematic review was registered in PROSPERO, CRD42017060379.


Subject(s)
Cytokines/metabolism , Transcutaneous Electric Nerve Stimulation/methods , Cytokines/immunology , Humans , Interleukin-6/immunology , Interleukin-6/metabolism , Pain/immunology , Pain/metabolism
3.
Eur J Pharm Sci ; 111: 133-141, 2018 Jan 01.
Article in English | MEDLINE | ID: mdl-28966097

ABSTRACT

This study aimed the development of nanocapsules (NCs) for oral indole-3-carbinol (I3C) administration and evaluation of antinociceptive potential of this compound in its two forms, free and nanoencapsulated, using acute pain models. NCs showed adequate physicochemical characteristics and protected the I3C against UVC radiation exposure. It was observed no chemical bond between I3C and polymer by FTIR. Besides, X-ray and DSC analysis suggested that I3C was molecularly dispersed in NCs. The dialysis bag technique showed that almost 100% of the compound was released from NCs at 360min. Mathematical modeling demonstrated that this release occurred in two rates, with an initial burst effect followed by a slower release of I3C. Regarding the in vivo analysis, time-response curve showed that both forms of I3C caused an inhibition in inflammatory phase of nociception induced by formalin and increased the latency response in hot plate test. Interestingly, NCs were able to prolong the I3C effect in both tests. Furthermore, in dose-response curve, only I3C in its nanoencapsulated form presented effect on inflammatory phase of the formalin test. In conclusion, NCs to I3C incorporation presented adequate nanometric characteristics and prolonged its antinociceptive action in acute pain models tested.


Subject(s)
Analgesics/administration & dosage , Drug Carriers/chemistry , Indoles/administration & dosage , Nanocapsules/chemistry , Pain/drug therapy , Ultraviolet Rays , Analgesics/radiation effects , Analgesics/therapeutic use , Animals , Disease Models, Animal , Dose-Response Relationship, Drug , Drug Stability , Indoles/radiation effects , Indoles/therapeutic use , Inflammation , Male , Mice , Pain/immunology , Particle Size , Surface Properties
4.
Inflamm Res ; 66(7): 591-602, 2017 Jul.
Article in English | MEDLINE | ID: mdl-28386622

ABSTRACT

OBJECTIVE AND DESIGN: This study aimed to evaluate the effect of probucol in inflammatory hyperalgesia and leukocyte recruitment in mice. TREATMENT: Probucol at 0.3-3 mg/kg was administrated per oral 1 h before inflammatory stimulus.Author: Kindly check and confirm the affiliation 1 have been correctly processed or not and amend if necessary.Thank you. We have corrected affiliation 1. We added the information to the appropriate boxes. However the state and the postal code are in a different order when compared to the other affiliations. METHODS: Overt pain-like behaviors were determined by the number of abdominal writhings induced by phenyl-p-benzoquinone and acetic acid. Mechanical and thermal hyperalgesia induced by carrageenan were determined using an electronic anesthesiometer and hot plate apparatus, respectively. Leukocyte recruitment was evaluated by direct count or by determination of myeloperoxidase and N-acetylglucosaminidase activities. Antioxidant ability was determined by measurement of GSH levels, ABTS and FRAP assays. Cytokine production and NF-кB activation were evaluated by ELISA. Data were analyzed by ANOVA followed by Tukey's post-hoc. p < 0.05 was considered significant. RESULTS: Probucol reduced overt pain-like behavior, and carrageenan-induced mechanical and thermal hyperalgesia. These effects were accompanied by reduced leukocyte influx in both paw skin and peritoneum exudate. Probucol did not alter carrageenan-induced tissue antioxidant capacity at anti-inflammatory/analgesic dose. On the other hand, probucol inhibited carrageenan-induced IL-1ß, TNF-α and CXCL1 production as well as NF-кB activation. CONCLUSION: Probucol presents analgesic and anti-inflammatory activities by employing mechanisms other than its antioxidant properties. These mechanisms involve targeting of pro-inflammatory cytokines and NF-кB activation.


Subject(s)
Analgesics/pharmacology , Analgesics/therapeutic use , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Probucol/pharmacology , Probucol/therapeutic use , Acetic Acid , Animals , Behavior, Animal/drug effects , Benzoquinones , Carrageenan , Cytokines/immunology , Edema/chemically induced , Edema/drug therapy , Edema/immunology , Hot Temperature , Hyperalgesia/chemically induced , Hyperalgesia/drug therapy , Hyperalgesia/immunology , Leukocytes/drug effects , Leukocytes/immunology , Male , Mice , NF-kappa B/immunology , Pain/chemically induced , Pain/drug therapy , Pain/immunology , Peritoneal Cavity , Physical Stimulation , Skin/drug effects , Skin/immunology
5.
Toxins (Basel) ; 9(12)2017 12 19.
Article in English | MEDLINE | ID: mdl-29311537

ABSTRACT

Animal venoms comprise a complex mixture of components that affect several biological systems. Based on the high selectivity for their molecular targets, these components are also a rich source of potential therapeutic agents. Among the main components of animal venoms are the secreted phospholipases A2 (sPLA2s). These PLA2 belong to distinct PLA2s groups. For example, snake venom sPLA2s from Elapidae and Viperidae families, the most important families when considering envenomation, belong, respectively, to the IA and IIA/IIB groups, whereas bee venom PLA2 belongs to group III of sPLA2s. It is well known that PLA2, due to its hydrolytic activity on phospholipids, takes part in many pathophysiological processes, including inflammation and pain. Therefore, secreted PLA2s obtained from animal venoms have been widely used as tools to (a) modulate inflammation and pain, uncovering molecular targets that are implicated in the control of inflammatory (including painful) and neurodegenerative diseases; (b) shed light on the pathophysiology of inflammation and pain observed in human envenomation by poisonous animals; and, (c) characterize molecular mechanisms involved in inflammatory diseases. The present review summarizes the knowledge on the nociceptive and antinociceptive actions of sPLA2s from animal venoms, particularly snake venoms.


Subject(s)
Analgesia/methods , Analgesics/pharmacology , Pain/drug therapy , Phospholipases A2, Secretory/pharmacology , Venoms/enzymology , Analgesics/therapeutic use , Animals , Humans , Pain/immunology , Phospholipases A2, Secretory/therapeutic use
6.
Trends Immunol ; 38(1): 5-19, 2017 Jan.
Article in English | MEDLINE | ID: mdl-27793571

ABSTRACT

Nociceptor sensory neurons protect organisms from danger by eliciting pain and driving avoidance. Pain also accompanies many types of inflammation and injury. It is increasingly clear that active crosstalk occurs between nociceptor neurons and the immune system to regulate pain, host defense, and inflammatory diseases. Immune cells at peripheral nerve terminals and within the spinal cord release mediators that modulate mechanical and thermal sensitivity. In turn, nociceptor neurons release neuropeptides and neurotransmitters from nerve terminals that regulate vascular, innate, and adaptive immune cell responses. Therefore, the dialog between nociceptor neurons and the immune system is a fundamental aspect of inflammation, both acute and chronic. A better understanding of these interactions could produce approaches to treat chronic pain and inflammatory diseases.


Subject(s)
Immune System , Inflammation/immunology , Neuroimmunomodulation , Nociceptors/metabolism , Pain/immunology , Sensory Receptor Cells/immunology , Adaptive Immunity , Animals , Humans , Immunity, Innate , Neuropeptides/metabolism , Neurotransmitter Agents/metabolism
7.
Molecules ; 21(12)2016 Dec 21.
Article in English | MEDLINE | ID: mdl-28009853

ABSTRACT

Riparins, natural alkaloids of the alkamide group, can be synthesized by simple methods, enhancing their potential application in pharmaceutical development. Here, the pharmacological properties of riparins were investigated in in vitro and in vivo assays of pain and inflammation in Swiss mice. Inflammatory mediators were measured by radioimmunoassay and Real-Time PCR. Riparins I, II, III and IV (1.56-100 mg/kg; ip) produced dose-related antinociceptive effects in the formalin test, exhibiting ED50 values of 22.93, 114.2, 31.05 and 6.63 mg/kg, respectively. Taking the greater potency as steering parameter, riparin IV was further investigated. Riparin IV did not produce antinociceptive effect on the tail flick, suggesting that its antinociception is not a centrally-mediated action. In fact, riparin IV (1.56-25 mg/kg) produced dose-related antinociceptive and antiedematogenic effects on the complete Freund's adjuvant (CFA)-induced paw inflammation in mice. During CFA-induced inflammation, riparin IV did not modulate either the production of cytokines, TNF-α and IL-10, or COX-2 mRNA expression. On the other hand, riparin IV decreased the PGE2 levels in the inflamed paw. In in vitro assays, riparin IV did not exhibit suppressive activities in activated macrophages. These results indicate, for the first time, that riparin IV induces antinociceptive and anti-inflammatory effects, possibly through the inhibition of prostanoid production.


Subject(s)
Alkaloids/pharmacology , Analgesics/pharmacology , Anti-Inflammatory Agents/pharmacology , Benzamides/pharmacology , Edema/drug therapy , Pain/drug therapy , Animals , Cyclooxygenase 2/genetics , Cyclooxygenase 2/immunology , Dinoprostone/antagonists & inhibitors , Dinoprostone/biosynthesis , Dinoprostone/immunology , Edema/chemically induced , Edema/immunology , Edema/pathology , Freund's Adjuvant/adverse effects , Gene Expression , Inflammation , Interleukin-10/genetics , Interleukin-10/immunology , Male , Mice , Pain/chemically induced , Pain/immunology , Pain/pathology , Pain Management , Pain Measurement , Pain Perception/drug effects , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/immunology
8.
J Allergy Clin Immunol ; 138(3): 700-710, 2016 09.
Article in English | MEDLINE | ID: mdl-27448446

ABSTRACT

Mast cells (MCs), which are granulated tissue-resident cells of hematopoietic lineage, contribute to vascular homeostasis, innate/adaptive immunity, and wound healing. However, MCs are best known for their roles in allergic and inflammatory diseases, such as anaphylaxis, food allergy, rhinitis, itch, urticaria, atopic dermatitis, and asthma. In addition to the high-affinity IgE receptor (FcεRI), MCs express numerous G protein-coupled receptors (GPCRs), which are the largest group of membrane receptor proteins and the most common targets of drug therapy. Antimicrobial host defense peptides, neuropeptides, major basic protein, eosinophil peroxidase, and many US Food and Drug Administration-approved peptidergic drugs activate human MCs through a novel GPCR known as Mas-related G protein-coupled receptor X2 (MRGPRX2; formerly known as MrgX2). Unique features of MRGPRX2 that distinguish it from other GPCRs include their presence both on the plasma membrane and intracellular sites and their selective expression in MCs. In this article we review the possible roles of MRGPRX2 on host defense, drug-induced anaphylactoid reactions, neurogenic inflammation, pain, itch, and chronic inflammatory diseases, such as urticaria and asthma. We propose that host defense peptides that kill microbes directly and activate MCs through MRGPRX2 could serve as novel GPCR targets to modulate host defense against microbial infection. Furthermore, mAbs or small-molecule inhibitors of MRGPRX2 could be developed for the treatment of MC-dependent allergic and inflammatory disorders.


Subject(s)
Mast Cells/immunology , Nerve Tissue Proteins/immunology , Receptors, G-Protein-Coupled/immunology , Receptors, Neuropeptide/immunology , Anaphylaxis/immunology , Animals , Chronic Disease , Drug Hypersensitivity/immunology , Humans , Immunity, Cellular , Inflammation/immunology , Pain/immunology
9.
Fundam Clin Pharmacol ; 30(1): 14-22, 2016 Feb.
Article in English | MEDLINE | ID: mdl-26791997

ABSTRACT

Nerolidol, an acyclic sesquiterpene found as a major constituent of several essential oils, has several pharmacological activities, but its action in pain processes has never been studied. The purpose of our research was to evaluate the antinociceptive and anti-inflammatory activities of nerolidol, as well as possible mechanisms of action, in experimental mouse models of pain. Antinociceptive activity was evaluated using the acetic acid-induced writhing test, the formalin test, and the hot-plate test. The nerolidol-treated group showed lesser acetic acid-induced abdominal contractions than the control group in all of the three doses tested (200, 300, and 400 mg/kg, p.o.). The formalin test doses of 300 and 400 mg/kg p.o. inhibited licking time, in both the first phase and the second phase. In the hot-plate test, nerolidol did not alter latency at any of the observed time points. Motor coordination, evaluated through the rotarod test, was not hindered in animals treated with nerolidol. Regarding the mechanism of action, the antinociceptive activity of nerolidol is related to the GABAergic system, and not to the opioidergic or ATP-sensitive K(+) channels. Treatment with nerolidol reduced carrageenan-induced paw edema. In the model of carrageenan-induced peritonitis, nerolidol decreased the influx of polymorphonuclear cells and also reduced levels of tumor necrosis factor (TNF-α) in peritoneal lavage. Nerolidol reduced production of interleukin 1 beta (IL-1ß) in LPS-stimulated, peritoneal macrophages. Thus, these results showed that nerolidol has antinociceptive activity with possible involvement of the GABAergic system, and anti-inflammatory activity, attributed to the suppression of TNF-α and IL-1ß proinflammatory cytokines.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Cytokines/metabolism , Pain/drug therapy , Receptors, GABA-A/metabolism , Sesquiterpenes/therapeutic use , Administration, Oral , Animals , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Cells, Cultured , Cytokines/immunology , Dose-Response Relationship, Drug , Edema/drug therapy , Edema/immunology , KATP Channels/metabolism , Macrophages/drug effects , Macrophages/immunology , Male , Mice , Pain/immunology , Pain/metabolism , Pain Measurement , Pain Threshold/drug effects , Peritonitis/drug therapy , Peritonitis/immunology , Rotarod Performance Test , Sesquiterpenes/administration & dosage
10.
Naunyn Schmiedebergs Arch Pharmacol ; 388(11): 1211-21, 2015 Nov.
Article in English | MEDLINE | ID: mdl-26246053

ABSTRACT

Bosentan is a mixed endothelin receptor antagonist widely used to treat patients with pulmonary arterial hypertension, and the emerging literature suggests bosentan as a potent anti-inflammatory drug. Superoxide anion is produced in large amounts during inflammation, stimulates cytokine production, and thus contributes to inflammation and pain. However, it remains to be determined whether endothelin contributes to the inflammatory response triggered by the superoxide anion. The present study investigated the effects of bosentan in a mouse model of inflammation and pain induced by potassium superoxide, a superoxide anion donor. Male Swiss mice were treated with bosentan (10-100 mg/kg) by oral gavage, 1 h before potassium superoxide injection, and the inflammatory response was evaluated locally and at spinal cord (L4-L6) levels. Bosentan (100 mg/kg) inhibited superoxide anion-induced mechanical and thermal hyperalgesia, overt pain-like behavior (abdominal writhings, paw flinching, and licking), paw edema, myeloperoxidase activity (neutrophil marker) in the paw skin, and leukocyte recruitment in the peritoneal cavity. Bosentan also inhibited superoxide anion-induced interleukin-1 beta (IL-1ß) and tumor necrosis factor alpha (TNF-α) production, while it enhanced IL-10 production in the paw skin and spinal cord. Bosentan inhibited the reduction of antioxidant capacity (reduced glutathione, ferric reducing antioxidant power, and ABTS radical scavenging ability) induced by the superoxide anion. Finally, we demonstrated that intraplantar injection of potassium superoxide induces the mRNA expression of prepro-endothelin-1 in the paw skin and spinal cord. In conclusion, our results demonstrated that superoxide anion-induced inflammation, pain, cytokine production, and oxidative stress depend on endothelin; therefore, these responses are amenable to bosentan treatment.


Subject(s)
Analgesics/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Endothelin Receptor Antagonists/therapeutic use , Hyperalgesia/drug therapy , Pain/drug therapy , Sulfonamides/therapeutic use , Analgesics/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Bosentan , Cytokines/immunology , Endothelin Receptor Antagonists/pharmacology , Hyperalgesia/chemically induced , Hyperalgesia/immunology , Leukocytes/drug effects , Leukocytes/immunology , Male , Mice , Pain/chemically induced , Pain/immunology , Peritoneal Cavity/cytology , Peroxidase/immunology , Skin/drug effects , Skin/immunology , Spinal Cord/drug effects , Spinal Cord/immunology , Sulfonamides/pharmacology , Superoxides
11.
Pharm Biol ; 51(10): 1262-71, 2013 Oct.
Article in English | MEDLINE | ID: mdl-23855752

ABSTRACT

UNLABELLED: CONTEXT. Tephrosia toxicaria is currently known as Tephrosia sinapou (Buc'hoz) A. Chev. (Fabaceae) and is a source of compounds such as flavonoids that inhibit inflammatory pain. OBJECTIVE: To investigate the analgesic effect and mechanisms of the ethyl acetate extract of T. sinapou in inflammatory pain in mice. MATERIALS AND METHODS: Behavioral responses were evaluated using mechanical (1-24 h) and thermal hyperalgesia (0.5-5 h), writhing response (20 min) and rota-rod (1-5 h) tests. Neutrophil recruitment (myeloperoxidase activity), cytokines (tumor necrosis factor [TNF]α and interleukin [IL]-1ß), aspartate aminotransferase (AST) and alanine aminotransferase (ALT) serum levels were determined by colorimetric assays. Pharmacological treatments were opioid receptor antagonist (naloxone, 0.1-1 mg/kg) and control opioid (morphine, 5 mg/kg). Inflammatory stimuli were carrageenin (100 µg/paw), complete Freund's adjuvant (CFA, 10 µl/paw), prostaglandin E2 (PGE2, 100 ng/paw) and acetic acid (0.8%). RESULTS: The intraperitoneal pre-treatment with extract inhibited in a dose-dependent (30-300 mg/kg) dependent manner the mechanical hyperalgesia induced by carrageenin (up to 93% inhibition). The post-treatment (100 mg/kg) inhibited CFA-induced hyperalgesia (up to 63% inhibition). Naloxone (1 mg/kg) prevented the inhibitory effect of the extract over carrageenin-induced mechanical (100%) and thermal (100%) hyperalgesia, neutrophil recruitment (52%) and TNFα (63%) and IL-1ß (98%) production, thermal threshold in naïve mice (99%), PGE2-induced mechanical hyperalgesia (88%) and acetic acid-induced writhing response (49%). There was no significant alteration in the rota-rod test, and AST and ALT serum levels by extract treatment. Discussion and conclusion. Tephrosia sinapou ethyl acetate extract reduces inflammatory pain by activating an opioid receptor-dependent mechanism.


Subject(s)
Analgesics/pharmacology , Hyperalgesia/prevention & control , Interleukin-1beta/metabolism , Pain/prevention & control , Plant Extracts/pharmacology , Receptors, Opioid/drug effects , Tephrosia , Tumor Necrosis Factor-alpha/metabolism , Acetates/chemistry , Analgesics/chemistry , Analgesics/isolation & purification , Animals , Behavior, Animal/drug effects , Disease Models, Animal , Dose-Response Relationship, Drug , Hyperalgesia/chemically induced , Hyperalgesia/immunology , Hyperalgesia/metabolism , Hyperalgesia/physiopathology , Male , Mice , Narcotic Antagonists/pharmacology , Neutrophil Infiltration/drug effects , Pain/chemically induced , Pain/immunology , Pain/metabolism , Pain/physiopathology , Pain Threshold/drug effects , Phytotherapy , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Plant Roots , Plants, Medicinal , Receptors, Opioid/metabolism , Signal Transduction/drug effects , Solvents/chemistry , Tephrosia/chemistry , Time Factors
12.
Naunyn Schmiedebergs Arch Pharmacol ; 386(7): 575-87, 2013 Jul.
Article in English | MEDLINE | ID: mdl-23584602

ABSTRACT

Valproic acid (VA) is a major antiepileptic drug, used for several therapeutic indications. It has a wide activity spectrum, reflecting on mechanisms of action that are not fully understood. The objectives of this work were to study the effects of VA on acute models of nociception and inflammation in rodents. VA (0.5, 1, 10, 25, and 50 mg/kg, p.o.) effects were evaluated on the carrageenan-induced paw edema, carrageenan-induced peritonitis, and plantar tests in rats, as well as by the formalin test in mice. The HE staining and immunohistochemistry assay for TNF-α in carrageenan-induced edema, from paws of untreated and VA-treated rats, were also carried out. VA decreased paw edema after carrageenan, and maximum effects were seen with doses equal to or higher than 10 mg/kg. VA also preserved the tissue architecture as assessed by the HE staining. Immunohistochemical studies revealed that VA significantly reduced TNF-α immunostaining in carrageenan-inflamed rat paws. In addition, the anti-inflammatory action of VA was potentiated by pentoxifylline (a phosphodiesterase inhibitor, known to inhibit TNF-α production), but not by sodium butyrate or by suberoylanilide hydroxamic acid (SAHA), nonspecific and specific inhibitors, respectively, of histone deacetylase. However, the decrease in the number of positive TNF-α cells in the rat paw was drastically potentiated in the VA + SAHA associated group. VA also reduced leukocytes and myeloperoxidase (MPO) releases to the peritoneal exudate, in the carrageenan-induced peritonitis. Although in the formalin test, VA inhibited both phases, the inhibition was mainly on the second phase. Furthermore, VA significantly increased the reaction time to thermal stimuli, as assessed by the plantar test. VA is a multi-target drug, presenting potent antinociceptive and anti-inflammatory properties at a lower dose range. These effects are partly dependent upon its inhibitory action on TNF-α-related pathways. However, the participation of the HDAC inhibition with the VA anti-inflammatory action cannot be ruled out. Inflammatory processes are associated with free radical damage and oxidative stress, and their blockade by VA could also explain the present results.


Subject(s)
Analgesics/administration & dosage , Anti-Inflammatory Agents/administration & dosage , Anticonvulsants/administration & dosage , Edema/drug therapy , Valproic Acid/administration & dosage , Animals , Butyric Acid/administration & dosage , Carrageenan , Drug Synergism , Edema/chemically induced , Edema/immunology , Edema/pathology , Foot/pathology , Formaldehyde , Hot Temperature , Hydroxamic Acids/administration & dosage , Leukocyte Count , Male , Mice , Pain/drug therapy , Pain/etiology , Pain/immunology , Pain/pathology , Pentoxifylline/administration & dosage , Peritonitis/chemically induced , Peritonitis/drug therapy , Peritonitis/immunology , Peroxidase/immunology , Rats , Rats, Wistar , Tumor Necrosis Factor-alpha/immunology , Vorinostat
13.
J Ethnopharmacol ; 146(1): 324-30, 2013 Mar 07.
Article in English | MEDLINE | ID: mdl-23313951

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Couroupita guianensis Aublet, 'macacarecuia', 'abricó-de-macaco', 'castanha-de-macaco' and 'amêndoa-dos-andes', is found in tropical regions and is widely used in the treatment of tumors, pain, and inflammatory processes. AIM OF THE STUDY: Ethanol extract and hexane and ethyl acetate fractions were evaluated in models of inflammatory pain (formalin-induced licking) and acute inflammation (carrageenan-induced peritonitis). MATERIALS AND METHODS: Ethanol extract, hexane and ethyl acetate fractions (10, 30 or 100 mg/kg, p.o.) and the reference drugs dexamethasone (5 mg/kg), morphine (5 mg/kg, s.c.), and acetylsalicylic acid (100 mg/kg, p.o.) were tested in formalin-induced licking response and carrageenan-induced peritonitis. RESULTS: All three doses from Couroupita guianensis fractions significantly reduced the time that the animal spent licking the formalin-injected paw in first and second phases. However, only higher doses (30 and 100 mg/kg) were able to inhibit the leukocyte migration into the peritoneal cavity after carrageenan injection. In this model, the 100 mg/kg dose almost abolished the cell migration. It was also observed that protein concentration resulted from extravasation to the peritoneum and nitric oxide (NO) productions were significantly reduced. Cytokines production was differently affected by the treatment. TNF-α production was reduced after ethanol extract and ethyl acetate fraction pre-treatment whereas hexane fraction had effect only with 100 mg/kg dose. IL-1ß production was inhibited only after hexane fraction pre-treatment. The inhibitory effect observed was not due to a direct cytotoxic effect on cells nor to a NO-scavenger activity. The effect was due to a direct inhibition on NO production by the cells. CONCLUSIONS: The results show that Couroupita guianensis fractions have anti-inflammatory effect, partly due to a reduction on cell migration and a inhibition on cytokines and inflammatory mediators production.


Subject(s)
Anti-Inflammatory Agents/therapeutic use , Lecythidaceae , Pain/drug therapy , Peritonitis/drug therapy , Plant Extracts/therapeutic use , Animals , Anti-Inflammatory Agents/pharmacology , Carrageenan , Cell Line , Cell Migration Assays, Leukocyte , Cell Survival/drug effects , Cytokines/immunology , Ethanol/chemistry , Formaldehyde , Male , Mice , Nitric Oxide/metabolism , Pain/chemically induced , Pain/immunology , Pain/physiopathology , Peritonitis/chemically induced , Peritonitis/immunology , Peritonitis/physiopathology , Phytotherapy , Plant Extracts/pharmacology , Plant Leaves , Solvents/chemistry
14.
Br J Pharmacol ; 169(1): 90-101, 2013 May.
Article in English | MEDLINE | ID: mdl-23347081

ABSTRACT

BACKGROUND AND PURPOSE: IL-33 signals through ST2 receptors and induces adaptive and innate inflammation. IL-33/ST2 is involved in adaptive inflammation-induced pain. Here, we have investigated the contribution of IL-33/ST2-triggered mechanisms to carrageenin-induced innate inflammation. EXPERIMENTAL APPROACH: Carrageenin- and IL-33-induced inflammatory responses were assessed in BALB/c- (WT) and ST2-deficient ((-/-) ) mice as follows: oedema (plethysmometer), myeloperoxidase activity (colorimetric assay), mechanical hyperalgesia (electronic version of von Frey filaments), cytokine levels (ELISA), PGE2 (RIA), mRNA expression (quantitative PCR), drug treatments targeting leukocyte recruitment (fucoidin), TNF-α (infliximab), CXCL1 (antibody to CXCL1), IL-1 (IL-1ra), endothelin ETA (clazosentan) and ETB (BQ788) receptors and COX (indomethacin). KEY RESULTS: Carrageenin injection increased ST2 and IL-33 mRNA expression and IL-33 production in paw skin samples. Carrageenin-induced paw oedema, hyperalgesia and myeloperoxidase activity were reduced in ST2(-/-) compared with WT mice, effects mimicked by IL-33 injection in the paw. Furthermore, IL-33-induced hyperalgesia was reduced by fucoidin suggesting a role for recruited leukocytes in its hyperalgesic effect. IL-33-induced hyperalgesia in naïve mice was reduced by treatments targeting TNF, CXCL1, IL-1, endothelin receptors and COX while carrageenin-induced ST2-dependent TNF-α, CXCL1, IL-1ß, IL-10 and PGE2 production and preproET-1 mRNA expression. Combining IL-33 and carrageenin at doses that were ineffective as single treatment induced significant hyperalgesia, oedema, myeloperoxidase activity and cytokine production in a ST2-dependent manner. CONCLUSIONS AND IMPLICATIONS: IL-33/ST2 signalling triggers the production of inflammatory mediators contributing to carrageenin-induced inflammation. These data reinforces the importance of IL-33/ST2 signalling as a target in innate inflammation and inflammatory pain.


Subject(s)
Inflammation/pathology , Interleukins/metabolism , Pain/pathology , Receptors, Interleukin/metabolism , Animals , Carrageenan/toxicity , Cytokines/metabolism , Dinoprostone/metabolism , Disease Models, Animal , Dose-Response Relationship, Drug , Endothelin-1/metabolism , Female , Inflammation/immunology , Inflammation Mediators/metabolism , Interleukin-1 Receptor-Like 1 Protein , Interleukin-33 , Interleukins/genetics , Male , Mice , Mice, Inbred BALB C , Mice, Knockout , Pain/etiology , Pain/immunology , RNA, Messenger/metabolism , Receptors, Interleukin/genetics , Signal Transduction/physiology
15.
J Ethnopharmacol ; 142(1): 59-64, 2012 Jun 26.
Article in English | MEDLINE | ID: mdl-22575213

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: The 3ß, 6ß, 16ß-trihydroxylup-20(29)-ene (TTHL) is a pentacyclic triterpene obtained from a medicinal plant named Combretum leprosum. In folk medicine, this plant is used to treat several diseases associated with inflammation and pain. We previously demonstrated that TTHL presents a significant antinociceptive effect, suggesting the involvement of the glutamatergic system. AIM OF THE STUDY: This study was designed to investigate the effect of TTHL on nociception and vascular permeability induced by acetic acid. We also evaluated the effect of TTHL on carrageenan-induced peritonitis and the levels of cytokines (interleukin 1-ß [IL-1ß], tumor necrosis factor α [TNF-α] and interleukin 10 [IL-10]) on peritoneal fluid. MATERIALS AND METHODS: TTHL was administered orally by intra-gastric gavage (i.g.) 60 min prior to experimentation. Abdominal contractions and vascular permeability were induced by an intraperitoneal (i.p.) injection of acetic acid (0.6%). We also investigated whether TTHL decreases carrageenan-induced peritonitis (750 µg/cavity) by measuring leukocyte migration and vascular permeability. In addition, we evaluated the effects of TTHL on TNF-α, IL-1ß and IL-10 release induced by carrageenan on peritoneal fluid. The levels of these cytokines were measured by ELISA. RESULTS: TTHL (0.01-10 mg/kg) administered by intra-gastric (i.g.) gavage inhibited (69±3%) acetic acid-induced abdominal constrictions, with an ID50 of 0.15 (0.03-0.8) mg/kg. TTHL (10mg/kg) also reduced the leukocyte infiltration induced by acetic acid, with an inhibition of 59±9 but had no effect on abdominal vascular permeability. In addition, indomethacin (10 mg/kg, i.p.) reduced the nociceptive behavior (92±1%), total leukocyte migration (29±3%) and capillary permeability (71±3%) induced by acetic acid. While the glucocorticoid dexamethasone (2 mg/kg, s.c.) reduced partially but significantly the nociception (31±1%), besides to promote a marked reduction on total leukocyte migration (60±2%) to the peritoneal cavity caused by acetic acid. In a model of peritonitis induced by carrageenan, TTHL also reduced total leukocyte migration, mainly neutrophils (inhibition of 84±3% and 85±2% at 30 mg/kg and 100 mg/kg, respectively). Likewise, dexamethasone (0.5 mg/kg, i.p.) resulted in an inhibition of 93±3%. Nevertheless, carrageenan-induced abdominal vascular permeability was reduced by dexamethasone but was not altered by TTHL. Furthermore, dexamethasone and TTHL significantly reduced the TNF-α and IL-1ß levels in peritoneal fluid, whereas the IL-10 levels were unchanged. CONCLUSIONS: Altogether, our data confirm the antinociceptive effect of TTHL and demonstrate its effect in inflammatory animal models, providing novel data about this compound, which could be useful as an anti-inflammatory drug.


Subject(s)
Analgesics/therapeutic use , Anti-Inflammatory Agents/therapeutic use , Combretum , Pain/drug therapy , Peritonitis/drug therapy , Triterpenes/therapeutic use , Acetic Acid , Analgesics/pharmacology , Animals , Anti-Inflammatory Agents/pharmacology , Ascitic Fluid/immunology , Capillary Permeability , Carrageenan , Cytokines/immunology , Disease Models, Animal , Leukocyte Count , Male , Mice , Pain/chemically induced , Pain/immunology , Pain/physiopathology , Peritonitis/chemically induced , Peritonitis/immunology , Peritonitis/physiopathology , Phytotherapy , Triterpenes/pharmacology
16.
Amino Acids ; 40(1): 101-11, 2011 Jan.
Article in English | MEDLINE | ID: mdl-20177946

ABSTRACT

Stings by bees and wasps, including Brazilian species, are a severe public health problem. The local reactions observed after the envenoming includes typical inflammatory response and pain. Several studies have been performed to identify the substances, including peptides that are responsible for such phenomena. The aim of the present study is to characterize the possible nociceptive (hyperalgesic) and edematogenic effects of some peptides isolated from the venoms of the honeybee (Apis mellifera) and the social wasps Polybia paulista and Protonectarina sylveirae, in addition to characterize some of the mechanisms involved in these phenomena. For this purpose, different doses of the peptides mellitin (Apis mellifera), Polybia-MP-I, N-2-Polybia-MP-I (Polybia paulista), Protonectarina-MP-NH2 and Protonectarina-MP-OH (Protonectarina sylveirae) were injected into the hind paw of mice. Hyperalgesia and edema were determined after peptide application, by using an electronic von Frey apparatus and a paquimeter. Carrageenin and saline were used as controls. Results showed that melittin, Polybia-MP-I, N-2-Polybia-MP-I, Protonectarina-MP-NH(2) and Protonectarina-MP-OH peptides produced a dose- and time-related hyperalgesic and edematogenic responses. Both phenomena are detected 2 h after melittin, Polybia-MP-I, N-2-Polybia-MP-I injection; their effects lasted until 8 h. In order to evaluate the role of prostanoids and the involvement of lipidic mediators in hyperalgesia induced by the peptides, indomethacin and zileuton were used. Results showed that zileuton blocked peptide-induced hyperalgesia and induced a decrease of the edematogenic response. On the other hand, indomethacin did not interfere with these phenomena. These results indicate that melittin, Polybia-MP-I, N-2-Polybia-MP-I, Protonectarina-MP-NH(2), and Protonectarina-MP-OH peptides could contribute to inflammation and pain induced by insect venoms.


Subject(s)
Bee Venoms/adverse effects , Bees/chemistry , Bites and Stings/chemically induced , Edema/chemically induced , Hyperalgesia/chemically induced , Wasp Venoms/adverse effects , Animals , Bee Venoms/immunology , Bee Venoms/isolation & purification , Bites and Stings/immunology , Edema/immunology , Humans , Hyperalgesia/immunology , Male , Mice , Pain/chemically induced , Pain/immunology , Wasp Venoms/immunology , Wasp Venoms/isolation & purification , Wasps/chemistry
17.
Alethéia ; (28): 11-20, jul.-dez. 2008.
Article in English, Portuguese | Index Psychology - journals | ID: psi-43760

ABSTRACT

Clinicamente, as implicações da dor crônica manifestam-se em forma de estados depressivos, estresse e comprometimento da vida social. Esta alta associação tem levado pesquisadores em Psicologia da Saúde a estudarem os possíveis mecanismos psiconeuroimunólogicos implicados nessa relação. Este trabalho revisa o conceito de Dor Crônica e os comprometimentos fisiológicos decorrentes da longa exposição a esta condição, como a alteração funcional do eixo Hipotálamo-Pituitária-Adrenal (HPA), o papel do hormônio cortisol e o conceito de carga alostática. Conclusão: Faz-se necessário um maior número de estudos em psiconeuroimunologia para melhor definir a etiologia dos distintos mecanismos da dor crônica e para delinear possíveis intervenções clínicas(AU)


Clinically, patients often report depressive symptoms, stress and disruptive social lives. The association of these symptoms with pain has been leading researchers in Health Psychology to investigate the possible psychoneuroimmunologic mechanisms underpinning such interaction. This work reviews the concept of chronic pain and its physiological alterations due to the long term exposure to pain stressors, such as the compromising of the Hypothalamic-Pituitary-Adrenal Axis (HPAA), the role of cortisol and the concept of allostatic load. Conclusion: There is a current demand for a larger number of studies involving etiological aspects of the distinct mechanisms involving chronic pain and to support possible new interventions(AU)


Subject(s)
Humans , Pain/complications , Pain/immunology , Pain/psychology , Stress, Physiological , Hydrocortisone , Hormones , Depression , Behavioral Medicine , Quality of Life/psychology
18.
Aletheia ; (28): 11-20, jul.-dez. 2008.
Article in English | LILACS | ID: lil-527427

ABSTRACT

Clinicamente, as implicações da dor crônica manifestam-se em forma de estados depressivos, estresse e comprometimento da vida social. Esta alta associação tem levado pesquisadores em Psicologia da Saúde a estudarem os possíveis mecanismos psiconeuroimunólogicos implicados nessa relação. Este trabalho revisa o conceito de Dor Crônica e os comprometimentos fisiológicos decorrentes da longa exposição a esta condição, como a alteração funcional do eixo Hipotálamo-Pituitária-Adrenal (HPA), o papel do hormônio cortisol e o conceito de carga alostática. Conclusão: Faz-se necessário um maior número de estudos em psiconeuroimunologia para melhor definir a etiologia dos distintos mecanismos da dor crônica e para delinear possíveis intervenções clínicas.


Clinically, patients often report depressive symptoms, stress and disruptive social lives. The association of these symptoms with pain has been leading researchers in Health Psychology to investigate the possible psychoneuroimmunologic mechanisms underpinning such interaction. This work reviews the concept of chronic pain and its physiological alterations due to the long term exposure to pain stressors, such as the compromising of the Hypothalamic-Pituitary-Adrenal Axis (HPAA), the role of cortisol and the concept of allostatic load. Conclusion: There is a current demand for a larger number of studies involving etiological aspects of the distinct mechanisms involving chronic pain and to support possible new interventions.


Subject(s)
Humans , Pain/complications , Pain/immunology , Pain/psychology , Hydrocortisone , Stress, Physiological , Behavioral Medicine , Depression , Hormones , Quality of Life/psychology
19.
Eur J Pharmacol ; 597(1-3): 86-91, 2008 Nov 12.
Article in English | MEDLINE | ID: mdl-18789924

ABSTRACT

A glucan was extracted with hot water from the basidiomycete Pleurotus pulmonarius and shown to have a (1-->3)-linked beta-D-glucopyranosyl main-chain substituted at O-6 of every third unit by single beta-D-glucopyranosyl non-reducing end units. This was shown by mono- and bidimensional nuclear magnetic resonance (NMR) spectroscopy, methylation analysis, and a controlled Smith degradation. The glucan was tested for its effects on the acetic acid-induced writhing reaction in mice, a typical model for quantifying inflammatory pain. It caused a marked and dose-dependent anti-inflammatory response, demonstrated by the inhibition of leukocyte migration to injured tissues (82 +/- 6%) with an ID50 of 1.19 (0.74-1.92) mg/kg. Furthermore, animals previously treated with the glucan (3 mg/kg i.p.), showed a reduction of 85 +/- 5% of writhes, after receiving the acetic acid injection. Furthermore, in the formalin test, the glucan (3-30 mg/kg, i.p.) also caused significant inhibition of both the early (neurogenic pain) and the late phases (inflammatory pain) of formalin-induced licking. However, it was more potent and effective in relation to the late phase of the formalin test, with mean ID(50) values for the neurogenic and the inflammatory phases of > 30 and 12.9 (6.7-24.6) mg/kg and the inhibitions observed were 43 +/- 5% and 96 +/- 4%, respectively. These data showed that the glucan had potent anti-inflammatory and analgesic (antinociceptive) activities, possibly by the inhibition of pro-inflammatory cytokines.


Subject(s)
Analgesics/pharmacology , Anti-Inflammatory Agents/pharmacology , Glucans/pharmacology , Inflammation/prevention & control , Pain/prevention & control , Pleurotus , Acetic Acid , Analgesics/isolation & purification , Animals , Anti-Inflammatory Agents/isolation & purification , Behavior, Animal/drug effects , Capillary Permeability/drug effects , Cell Movement/drug effects , Disease Models, Animal , Dose-Response Relationship, Drug , Formaldehyde , Glucans/isolation & purification , Inflammation/chemically induced , Inflammation/immunology , Leukocytes/drug effects , Male , Mice , Molecular Structure , Pain/chemically induced , Pain/immunology , Pain Measurement , Pleurotus/chemistry
20.
Proc Natl Acad Sci U S A ; 105(7): 2723-8, 2008 Feb 19.
Article in English | MEDLINE | ID: mdl-18250323

ABSTRACT

IL-33, a new member of the IL-1 family, signals through its receptor ST2 and induces T helper 2 (Th2) cytokine synthesis and mediates inflammatory response. We have investigated the role of IL-33 in antigen-induced hypernociception. Recombinant IL-33 induced cutaneous and articular mechanical hypernociception in a time- and dose-dependent manner. The hypernociception was inhibited by soluble (s) ST2 (a decoy receptor of IL-33), IL-1 receptor antagonist (IL-1ra), bosentan [a dual endothelin (ET)(A)/ET(B) receptor antagonist], clazosentan (an ET(A) receptor antagonist), or indomethacin (a cyclooxygenase inhibitor). IL-33 induced hypernociception in IL-18(-/-) mice but not in TNFR1(-/-) or IFNgamma(-/-) mice. The IL-33-induced hypernociception was not affected by blocking IL-15 or sympathetic amines (guanethidine). Furthermore, methylated BSA (mBSA)-induced cutaneous and articular mechanical hypernociception depended on TNFR1 and IFNgamma and was blocked by sST2, IL-1ra, bosentan, clazosentan, and indomethacin. mBSA also induced significant IL-33 and ST2 mRNA expression. Importantly, we showed that mBSA induced hypernociception via the IL-33 --> TNFalpha --> IL-1beta --> IFNgamma --> ET-1 --> PGE(2) signaling cascade. These results therefore demonstrate that IL-33 is a key mediator of immune inflammatory hypernociception normally associated with a Th1 type of response, revealing a hitherto unrecognized function of IL-33 in a key immune pharmacological pathway that may be amenable to therapeutic intervention.


Subject(s)
Antigens/immunology , Interleukins/immunology , Pain/immunology , Skin/immunology , Aflatoxin B1/pharmacology , Animals , Dinoprostone/biosynthesis , Endothelin-1/genetics , Female , Gene Expression Regulation/drug effects , Male , Methylation , Mice , Mice, Knockout , Pain/chemically induced , Pain/pathology , RNA, Messenger/genetics , Serum Albumin/pharmacology , Skin/blood supply , Skin/drug effects , Skin/pathology
SELECTION OF CITATIONS
SEARCH DETAIL